Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors. Among individuals with ...

ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...

Please provide your email address to receive an email when new articles are posted on . Historically, patient-reported outcome measures were primarily used for research. Today, surgeons use ...

SAN DIEGO, June 2, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained ...

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the ...

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, ...

There is a lack of systematic solutions to manage supportive care issues in racial/ethnic minorities (REM) receiving treatment for cancer. We developed and implemented an electronic patient-reported ...

How can biotech companies use patient-reported outcomes to bring better drugs forward for patients? Generally, patient-reported outcomes (PROs) provide complementary information to measured or ...

Patient-reported outcomes (PROs) have rapidly become integral to cancer care, offering invaluable insights by capturing the patient’s perspective on symptoms, quality of life, and treatment-related ...

“It’s really hard to be a patient with cancer. Patients suffer a lot at home and don’t reach out,” Ethan Basch, MD, said. “Helping to have better communication to address their needs is really ...

When patients provide information about how they are doing, including symptoms, functionality, and quality of life, scientists can use this data, called patient-reported outcomes (PROs), to conduct ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global ...